Clinical Pipeline

Clinical Trials

To learn more about our ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov or email clinical@kadmon.com.

CandidatePhaseStudy
Number
Indication
BelumosudilPivotalKD025-213Chronic graft-versus-host disease (cGVHD) after at least 2 prior lines of systemic therapy
BelumosudilPhase 2KD025-208Chronic graft-versus-host disease (cGVHD) after 1-3 prior lines of systemic therapy
BelumosudilPhase 2KD025-209Diffuse Cutaneous Systemic Sclerosis (SSc)
BelumosudilPhase 2KD025-207Idiopathic Pulmonary Fibrosis (IPF)
TesevatinibPhase 2KD019-211Autosomal Dominant Polycystic Kidney (ADPKD)

At this time, Kadmon’s investigational therapies are not available on an expanded access or right-to-try basis for new patients.  In the event Kadmon decides to consider expanded access or right-to-try use, the Company will evaluate and respond to each request that it receives on a case-by-case basis. For more information on our investigational therapies and ongoing clinical trials, please visit Kadmon.com/clinicalpipeline or clinicaltrials.gov.